AVROBIO, Inc. (AVRO) analyst actions
Rating and price-target actions on AVRO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the AVRO overview →
1 measured AVRO analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure | Press release | -1.60% | +0.80% |
Keep exploring
More AVRO: earnings → · SEC filings → · AVRO overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SunLink Health Systems, Inc. (SSY) | 99 | 0.00% | 49% |
| ARNO THERAPEUTICS INC (ARNI) | 98 | 0.00% | 23% |
| LIFELOC TECHNOLOGIES INC (LCTC) | 97 | 0.00% | 19% |
| ORGANIGRAM HOLDINGS INC (OGRMF) | 97 | +0.25% | 56% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.